- Home
- VVR vs ALT Comparison
VVR vs ALT Comparison
Compare VVR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VVR | ALT |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.3M | 415.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VVR | ALT |
|---|---|---|
| Price | $3.29 | $4.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 692.2K | ★ 5.9M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 11.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.55 | $2.90 |
| 52 Week High | $4.38 | $7.73 |
Technical Indicators
Market Signals| Indicator | VVR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 50.65 |
| Support Level | $3.28 | $3.96 |
| Resistance Level | $3.31 | $4.40 |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 64.29 | 74.48 |
Price Performance
Historical ComparisonAbout VVR Invesco Senior Income Trust (DE)
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.